Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:1270 (28 May), doi:10.1136/bmj.330.7502.1270
| The first 150 words of the full text of this article appear below. |
EditorThe editorial by Verma and Strauss does not accord with the BMJ's usual impartial evidence based approach.1 Evidence that angiotensin receptor blockers increase myocardial infarction is scant, and I remain puzzled about what exactly patients should be toldthat the BMJ published an incorrect analysis?
Regarding angiotensin receptor blockers and myocardial infarction in hypertension, the data from the valsartan antihypertensive long term use evaluation (VALUE) trial, quoted by Verma and Strauss, can be added to a prior meta-analysis by the Blood Pressure Trialists.2 The incidence of coronary heart disease and myocardial infarction is 804/16061 (5%) in the treated groups and 763/15948 (4.78%) in the controls (odds ratio 1.046), a non-significant increase of myocardial infarction of 4.6% v controls, whereas lisinopril increased combined cardiovascular disease by 10%.3
Regarding candesartan and heart failure, in the predefined group of patients with low left ventricular ejection fractions (< 40%), candesartan reduced all cause mortality
Lionel H Opie, director1
1 Hatter Institute, University of Cape Town, Medical School, Observatory, Cape Town, South Africa opie@capeheart.uct.ac.za